InGef - Institut für angewandte Gesundheitsforschung Berlin GmbH

The Institut für angewandte Gesundheitsforschung Berlin (InGef) is a leading research institute that focuses on the further development of German healthcare. With practical research, InGef supports the conception and evaluation of new care models to improve the quality and efficiency of healthcare.

• Research Database: InGef has an extensive research database containing anonymized billing data from approximately 8.8 million statutorily insured individuals. This database makes it possible to process healthcare research projects and pharmacoepidemiological questions[1][3].
• Analysis Methods: The institute uses a broad spectrum of statistical methods, including cross-sectional studies, case-control studies, longitudinal cohort studies, and disease cost studies. Modern machine learning methods such as Deep Learning and Natural Language Processing are also used[3].
• Software Solutions: The innovative software solution EVA enables health insurance companies to analyze insured data quickly and easily[1].

InGef's mission is to explore current challenges in the healthcare system through research, to recognize connections, and to provide practical impulses for the future care of the population. InGef's aspiration is reflected in the maxim "Erforschen. Erkennen. Optimieren." [Research. Recognize. Optimize.][1].

InGef is committed to sustainable and quality-assured healthcare. Through the development and evaluation of new care models, the institute contributes to the long-term improvement of healthcare. It works according to the principles of Good Practice Secondary Data Analysis and the guidelines for ensuring Good Epidemiological Practice (GEP)[3].

In summary, InGef is a central player in German health research, contributing to the optimization of healthcare through innovative research and analysis methods.

• 1 - https://www.ingef.de
• 2 - https://pubmed.ncbi.nlm.nih.gov/35378455/
• 3 - https://www.ingef.de/gesundheitsforschung/methoden/
• 4 - https://www.g-ba.de/downloads/92-975-7627/2024_04_18_Modul3A_Abrocitinib.pdf
• 5 - https://catalogues.ema.europa.eu/institution/3331181